In line with your last point: Two factors not yet defined: 1) Would a lower dose provide SA improvement in some responder group (perhaps especially the 15-20% with a central apnea component) without reducing sleep? 2) Would chronic dosing cause a worsening of the sleep disturbance or might some tolerance occur over time, where the insomnia-induction effect is lessened?
It is pretty clear to me that the results show the 'signal' of impact we'd hoped for, in some segment of the SA population. Balancing that signal against the adverse event of sleep-reduction is what has to be accomplished if this is to ever turn into a real drug.
Market Data 
Markets 
AI
